Simplify Health Care ETF(PINK.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Simplify Health Care ETF
PINK.US
News
View More

'Top Healthcare Pick for 2026,' Says Bernstein on UnitedHealth Stock (UNH). Here's Why

Bernstein analyst Lance Wilkes maintains an Outperform rating on UnitedHealth Group (UNH), despite a 36% decline over the past year. He sets a $444 price target, calling it his "top healthcare pick for 2026." Wilkes anticipates a recovery in the health insurance sector, with margins improving in Medicare Advantage and Medicaid. He highlights UnitedHealth's strategic moves to enhance profitability and its potential for earnings growth. The stock has a Strong Buy consensus on Wall Street, with an average price target of $397.82, suggesting an 18.95% upside.

Tip Ranks·
US
UNH
-2.34%
Tip Ranks·
US
UNH
-2.34%

Mizuho Securities Sticks to Their Buy Rating for UnitedHealth (UNH)

Mizuho Securities analyst Ann Hynes has reaffirmed a Buy rating for UnitedHealth (UNH) with a price target of $430. Hynes, a 5-star analyst, has an average return of 7.7% and a 58.55% success rate. While Mizuho maintains a positive outlook, TipRanks also reported a Hold rating from DeepSeek on the same day. Hynes covers various stocks in the Healthcare sector, including BrightSpring Health Services and Centene.

Tip Ranks·
US
UNH
-2.34%
Tip Ranks·
US
UNH
-2.34%

UnitedHealth Faces New Medicare Accusations. What Does That Mean for UNH Stock?

UnitedHealth Faces New Medicare Accusations. What Does That Mean for UNH Stock?

Barchart Option·
US
UNH
-2.34%
Barchart Option·
US
UNH
-2.34%

UnitedHealth Group Incorporated $UNH Holdings Lifted by Rakuten Securities Inc.

Rakuten Securities Inc. increased its holdings in UnitedHealth Group (NYSE:UNH) by 83.6% in Q3, owning 16,194 shares valued at $5.59 million. The stock represents 2.1% of its portfolio. Other investors also acquired stakes in UNH. The stock opened at $334.55, with a market cap of $303.05 billion and a P/E ratio of 17.46. UnitedHealth reported Q3 earnings of $2.92 per share, exceeding estimates, with revenue of $113.16 billion. The company declared a quarterly dividend of $2.21, yielding 2.6%. Analysts have mixed ratings on the stock, with a consensus price target of $385.75.

Market Beat·
US
UNH
-2.34%
Market Beat·
US
UNH
-2.34%

AbbVie plans to build out its presence in obesity market

AbbVie is expanding its presence in the obesity treatment market by leveraging Gubra's weight-loss drug, GUBamy, which mimics the hormone amylin. This drug aims to provide an alternative to GLP-1 drugs like Wegovy and Zepbound, focusing on better tolerability and durability of weight loss. AbbVie believes its existing aesthetics business positions it well, as patients seeking cosmetic treatments are also interested in weight loss solutions. The obesity drug market is projected to reach $150 billion in annual sales within the next decade.

Reuters·
US
ABBV
-0.31%
Reuters·
US
ABBV
-0.31%
© 2026 Longbridge｜Disclaimer